ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Traeger Receives NYSE Continued Listing Standard Notice

Notice Has No Immediate Impact on the Listing or Trading of Traeger Common Stock

Traeger, Inc. (“Traeger” or the “Company”) (NYSE: COOK) today announced that it has received a notice from the New York Stock Exchange (the “NYSE”) on November 19, 2025 indicating that the average closing price per share of its common stock was below $1.00 over a consecutive 30-day period, as required for continued listing on the NYSE.

The Company remains on track with executing Project Gravity, a strategic transformation initiative designed to enhance operational efficiency, improve profitability, and optimize return on investment. This program is expected to deliver approximately $50 million in annualized run-rate savings while unlocking capacity and resources to invest in the Company's highest-growth opportunities. As of September 30, 2025, the Company maintained a strong liquidity position of $167 million, providing a solid foundation to support strategic initiatives.

Under NYSE rules, the Company has six months following receipt of the NYSE notice to regain compliance with the minimum share price requirement. The Company has notified the NYSE of its intent to cure this deficiency, including, among other options, a reverse stock split, subject to approval by the Company’s Board of Directors and stockholders.

During the cure period, Traeger’s common stock will continue to be listed and traded on the NYSE, subject to compliance with other continued listing requirements. The Company can regain compliance at any time during the cure period if, on the last trading day of any calendar month, its common stock has a closing price of at least $1.00 per share and an average closing share price of at least $1.00 over the prior 30 trading-day period ending on the last trading day of the applicable calendar month or cure period. Under the NYSE’s rules, if the Company determines that it will cure the stock price deficiency by taking an action requiring shareholder approval at its next annual meeting, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the next 30 trading days.

The NYSE notice does not affect the Company’s ongoing business operations, its reporting obligations with the Securities and Exchange Commission, nor does it trigger any violation of its debt obligations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s plans with respect to the NYSE notice of non-compliance, including a potential reverse stock split and estimated annualized run-rate savings from Project Gravity. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: reactions from our employees, vendors, customers, lenders and investors to the Company’s receipt of the NYSE notice of non-compliance, the Company’s ability to regain compliance with the minimum share price requirement within the applicable cure period; the Company’s ability to comply with other NYSE listing standards and maintain the listing of its common stock on the NYSE; the impact of management transitions on our common stock; our ability to manage our future growth effectively; our ability to expand into additional markets; our ability to maintain and strengthen our brand to generate and maintain ongoing demand for our products; our ability to cost-effectively attract new customers and retain our existing customers; the highly competitive market in which we operate; and the ability of our stockholders to influence corporate matters. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.67
+0.00 (0.00%)
AAPL  276.97
+0.00 (0.00%)
AMD  206.13
+0.00 (0.00%)
BAC  52.48
+0.00 (0.00%)
GOOG  323.64
+0.00 (0.00%)
META  636.22
+0.00 (0.00%)
MSFT  476.99
+0.00 (0.00%)
NVDA  177.82
+0.00 (0.00%)
ORCL  197.03
+0.00 (0.00%)
TSLA  419.40
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.